The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment

Christina Darwish, Kyle Farina, Douglas Tremblay

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Core binding factor acute myeloid leukemia (CBF AML), defined by t(8;21) or inv(16), is a subset of favorable risk AML. Despite its association with a high complete remission rate after induction and relatively good prognosis overall compared with other subtypes of AML, relapse risk after induction chemotherapy remains high. Optimizing treatment planning to promote recurrence free survival and increase the likelihood of survival after relapse is imperative to improving outcomes. Recent areas of research have included evaluation of the role of gemtuzumab in induction and consolidation, the relative benefit of increased cycles of high dose cytarabine in consolidation, the utility of hypomethylating agents and kinase inhibitors, and the most appropriate timing of stem cell transplant. Surveillance with measurable residual disease testing is increasingly being utilized for monitoring disease in remission, and ongoing investigation seeks to determine how to use this tool for early identification of patients who would benefit from proceeding to transplant. In this review, we outline the current therapeutic approach from diagnosis to relapse while highlighting the active areas of investigation in each stage of treatment.

Original languageEnglish
Article number101117
JournalBlood Reviews
Volume62
DOIs
StatePublished - Nov 2023

Keywords

  • Core binding factor
  • Gemtuzumab
  • Measurable residual disease
  • Transplant
  • inv(16)
  • t(8;21)

Fingerprint

Dive into the research topics of 'The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment'. Together they form a unique fingerprint.

Cite this